The original instrument and the following digest, which constitutes no part of the legislative instrument, were prepared by Thomas L. Tyler.

DIGEST

SB 146 Original 2022 Regular Session Talbot

Present law prohibits denial of health insurance coverage for the treatment of metastatic or unresectable tumors with a medically necessary drug prescribed by a physician on the sole basis that the drug is not indicated for the location in the body of the patient's cancer if the drug is approved by the Food and Drug Administration for the treatment of the specific mutation of the patient's cancer. Provides that coverage may be denied if an alternative treatment has proven to be more effective in published randomized clinical trials and is not contraindicated in the patient.

Proposed law retains the present prohibition but applies it to the treatment of other advanced cancers and that the prohibition cannot be the basis that the drug is not indicated for the specific tumor type. Provides that the insurer may not deem the treatment experimental or outside of their policy scope. Provides that coverage may only be denied if an alternative treatment has proven to be more effective in published randomized clinical trials and is not contraindicated in the patient.

Effective on August 1, 2022.

(Amends R.S. 22:1054.1(A))